Aarti Pharmalabs Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The Board of Directors has recommended a final dividend of Rs. 2/- per equity share, subject to shareholder approval. The company reported a standalone net profit of Rs. 17,620.20 lakhs for the financial year. Additionally, the company made key leadership changes and reappointed its cost and internal auditors for the upcoming 2026-27 fiscal year.
Financial Performance Overview
For the financial year ended March 31, 2026, Aarti Pharmalabs reported standalone revenue from operations of Rs. 179,755.17 lakhs, compared to Rs. 177,135.18 lakhs in the previous year. The standalone net profit for the year stood at Rs. 17,620.20 lakhs. On a consolidated basis, the company achieved revenue from operations of Rs. 181,944.25 lakhs, with a consolidated net profit of Rs. 17,470.73 lakhs attributable to the owners of the company.
Dividend and Governance
The Board has recommended a final dividend of Rs. 2/- per equity share (a 40% payout) on shares with a face value of Rs. 5/- each. This dividend remains subject to approval by shareholders at the company’s upcoming Annual General Meeting.
In strategic governance updates, the company reappointed Smt. Ketki D. Visariya as the Cost Auditor and Manish Modi & Associates as the Internal Auditor for the 2026-27 financial year. Furthermore, Mr. Sachin Patil (Head – Exports) and Mr. Rajendra Pagare (Head – Operations & Compliance) have been designated as Senior Management Personnel, effective May 25, 2026.
Operational Developments
The company noted an impact on its financial results due to a target redemption forward contract entered during FY 2024-25. While initially omitted from fair value calculations, the hedge effectiveness is now measured at Fair Value Through Profit and Loss (FVTPL), with restated quarterly impacts included to ensure transparency. The company continues to operate within a single business segment, focusing on Pharmaceuticals.
Source: BSE
